Barclays PLC Vaxcyte, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Barclays PLC holds 209,753 shares of PCVX stock, worth $18.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

209,753

Previous 209,753 -0.0%

Holding current value

$18.6 Million

Previous $24 Million -0.0%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$70.52 - $117.12 $5.77 Million - $9.58 Million	81,801 Added 63.93%	209,753 $24 Million
Q2 2024 Aug 14, 2024	SELL	$60.06 - $78.77 $78,078 - $102,401	-1,300 Reduced 1.01%	127,952 $9.66 Million
Q1 2024 May 15, 2024	SELL	$59.79 - $81.05 $4.33 Million - $5.87 Million	-72,446 Reduced 35.92%	129,252 $8.83 Million
Q4 2023 Feb 15, 2024	BUY	$45.35 - $63.41 $1.42 Million - $1.98 Million	31,286 Added 18.36%	201,698 $12.7 Million
Q3 2023 Nov 07, 2023	BUY	$46.0 - $53.1 $3.17 Million - $3.66 Million	68,904 Added 67.88%	170,412 $8.69 Million
Q2 2023 Aug 03, 2023	BUY	$34.66 - $54.07 $322,441 - $503,013	9,303 Added 10.09%	101,508 $5.07 Million
Q1 2023 May 04, 2023	SELL	$36.27 - $47.2 $785,136 - $1.02 Million	-21,647 Reduced 19.01%	92,205 $3.46 Million
Q4 2022 Feb 13, 2023	BUY	$20.58 - $47.95 $1.11 Million - $2.58 Million	53,853 Added 89.76%	113,852 $5.46 Million
Q3 2022 Nov 03, 2022	BUY	$21.69 - $28.53 $1.24 Million - $1.64 Million	57,353 Added 2167.54%	59,999 $1.44 Million
Q2 2022 Aug 12, 2022	SELL	$17.68 - $26.58 $833,682 - $1.25 Million	-47,154 Reduced 94.69%	2,646 $58,000
Q1 2022 May 16, 2022	BUY	$17.46 - $26.36 $869,508 - $1.31 Million	49,800 New	49,800 $1.2 Million

Others Institutions Holding PCVX

# of Institutions

352

Shares Held

122M

Call Options Held

775K

Put Options Held

433K

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.25B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account